Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model

V. Faugeroux, E. Pailler, M. Oulhen, O. Deas, L. Brulle-Soumare, C. Hervieu, V. Marty, K. Alexandrova, K.C. Andree, N.H. Stoecklein, D. Tramalloni, S. Cairo, M. NgoCamus, C. Nicotra, L.W.M.M. Terstappen, N. Manaresi, V. Lapierre, K. Fizazi, J.-Y. Scoazec, Y. Loriot*J.-G. Judde, F. Farace*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

7 Citations (Scopus)
4 Downloads (Pure)

Abstract

Transformation of castration-resistant prostate cancer (CRPC) into an aggressive neuroendocrine disease (CRPC-NE) represents a major clinical challenge and experimental models are lacking. A CTC-derived eXplant (CDX) and a CDX-derived cell line are established using circulating tumor cells (CTCs) obtained by diagnostic leukapheresis from a CRPC patient resistant to enzalutamide. The CDX and the derived-cell line conserve 16% of primary tumor (PT) and 56% of CTC mutations, as well as 83% of PT copy-number aberrations including clonal TMPRSS2-ERG fusion and NKX3.1 loss. Both harbor an androgen receptor-null neuroendocrine phenotype, TP53, PTEN and RB1 loss. While PTEN and RB1 loss are acquired in CTCs, evolutionary analysis suggest that a PT subclone harboring TP53 loss is the driver of the metastatic event leading to the CDX. This CDX model provides insights on the sequential acquisition of key drivers of neuroendocrine transdifferentiation and offers a unique tool for effective drug screening in CRPC-NE management.
Original languageEnglish
Article number1884
JournalNature communications
Volume11
DOIs
Publication statusPublished - 20 Apr 2020

Fingerprint Dive into the research topics of 'Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model'. Together they form a unique fingerprint.

Cite this